Related Experiment Video

Updated: Oct 6, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future

Jin Yuan1, Xiaoyang Li1, Shengji Yu1

  • 1Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical sciences and Peking Union Medical College, Beijing, China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|January 20, 2022
PubMed

Insights

Targeting CDK7 (Cyclin-dependent kinase 7) addiction in cancer, particularly sarcomas, offers a new therapeutic strategy. Inhibiting CDK7 disrupts oncogenic transcription, showing promise for treating these aggressive tumors.

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • Pharmacology

Background:

  • Cancer cells exhibit genetic alterations leading to dysregulated transcriptional programs.
  • These programs create dependencies on specific gene expression regulators, such as CDK7.
  • CDK7 is crucial for transcription initiation and the expression of oncogenes in cancer.

Purpose of the Study:

  • To review the mechanism of CDK7-dependent transcriptional addiction in cancer.
  • To discuss the potential of targeting this addiction in bone and soft tissue sarcomas.
  • To provide theoretical considerations for developing bio-orthogonal therapeutic strategies.

Main Methods:

  • Review of existing literature on CDK7 function in cancer transcription.
  • Analysis of CDK7's role in super-enhancer-driven oncogene expression.
  • Exploration of therapeutic strategies targeting CDK7 in sarcoma models.

Main Results:

  • CDK7 inhibition reduces the recruitment of transcription factors to super-enhancers.
  • This inhibition leads to decreased expression of key oncogenes in cancer cells.
  • Sarcoma oncoproteins often rely on oncogenic transcription, highlighting CDK7 as a target.

Conclusions:

  • Cancer cells exhibit a 'transcriptional addiction' to CDK7.
  • Targeting CDK7-dependent transcription is a promising strategy for sarcoma treatment.
  • Further research is needed to develop effective bio-orthogonal therapies for sarcomas.
Keywords:
Bone and soft tissue sarcomasCDK7Super-enhancerTranscriptional addiction

More Related Videos

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.8K
Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.5K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K